![Pulse Picks: Top 10 entertainment stories that defined 2020 [ARTICLE]](https://ghanatoday.net/wp-content/uploads/2021/01/dFpktkpTURBXy80M2NmNDQ1NDZlOWQ3YjZjYzMxOWJlNWU4NmY5YzE3NS5qcGeSlQMACc0MwM0HLJMFzQMUzQG8-360x180.jpeg)
Inovio’s COVID-19 vaccine candidate shows promise in small early-stage trial
An experimental coronavirus vaccine developed by Inovio Pharmaceuticals Inc showed promise and was found to be safe in an early-stage human trial, the company said on Tuesday.
The vaccine, one of 17 being tested in humans and part of the Trump administration’s Operation Warp Speed program, induced immune responses in 34 of the 36 healthy volunteers aged 18 to 50 years, Inovio said.
The company, however, did not disclose more details on the exact response the vaccine induced, saying the full data will be published in a peer-reviewed medical journal later.
Shares of the company fell 10.1% to $28.49 as Wall Street analysts said the initial data provided only a limited look into the vaccine’s effects.
Immune responses in the study were measured by the vaccine’s ability to generate binding antibodies, or virus-neutralizing antibodies, and T-cell responses, two metrics considered vital for a successful vaccine.
